Clinical trials: Tumor of Bone
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Breast cancer and osteoporosis are two of the most frequent diseases in women. Estrogen may be associated with bone loss and the risk of breast cancer because of its potent effects on the mitotic activity of breast epithelium and…
- Trial name
- NCT00333229
- Testing
- Zoledronic Acid
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them…
- Trial name
- NCT00006045
- Testing
- lintuzumab, cytarabine, etoposide
- Where
- 59 sites in United States, Belgium and 5 more
- Sponsor
- Facet Biotech
Sarcoma
Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)
The study evaluates efficacy of Ridaforolimus when administered as maintenance therapy to patients with metastatic bone or soft-tissue sarcoma in Japan.
- Trial name
- NCT01010672
- Testing
- Ridaforolimus
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1
A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced Interbody Cages in the Lumbar Spine
The purpose of this trial is to collect clinical outcomes including radiographic and CT outcomes in patients who undergo interbody spinal fusion using the EVOS Lumbar Interbody System.
- Trial name
- NCT03928041
- Testing
- Device: EVOS Lumbar Interbody System (EVOS-HA)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Invibio Ltd
Chronic Myeloid Leukemia, CML
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
This prospective registry is initiated to follow up on the use of Iclusig® in patients with CML or Ph+ ALL in routine practice in Belgium.
- Conditions
- Chronic Myeloid Leukemia, CML, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia, Ph+ ALL
- Trial name
- NCT03678454
- Where
- 19 sites in Belgium
- Volunteers
- 80 people
- Sponsor
- Incyte Biosciences Benelux
Leiomyosarcoma, Liposarcoma
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Osteosarcoma, Sarcoma, Soft Tissue
- Trial name
- NCT00093080
- Testing
- ridaforolimus
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal…
- Trial name
- NCT00171704
- Testing
- Letrozole, Tamoxifen
- Where
- 13 sites in Denmark, United Kingdom
- Volunteers
- 263 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelodysplastic Syndromes
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Blast Crisis
- Trial name
- NCT00034684
- Testing
- Farnesyl Protein Transferase Inhibitor
- Volunteers
- 132 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Malignancy, Acute Myeloid Leukemia
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.
- Conditions
- Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03555955
- Testing
- CPX-351
- Where
- 13 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia
- Trial name
- NCT07719348
- Testing
- S241656, Posaconazole
- Volunteers
- 64 people
- Sponsor
- Servier
Myeloproliferative Neoplasms
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
- Trial name
- NCT06313593
- Testing
- INCB160058, Standard disease-directed therapy
- Where
- 30 sites in United States, Canada and 6 more
- Volunteers
- 37 people
- Sponsor
- Incyte Corporation
Bone Lesion, Bone Tumor
Augmented Reality Navigation System (Endosight) for the Guidance of Bone Biopsy
The goal of this clinical study is to evaluate the duration of the procedure, the precision (distance between the needle tip and the centre of the target), and the safety of endosight system in the guidance for bone biopsies.
- Conditions
- Bone Lesion, Bone Tumor, Bone Infection
- Trial name
- NCT05732558
- Testing
- 8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- R.A.W. - S.R.L.
Intervertebral Disc Disease, Spondylolisthesis
PASS OCT® Post-market Clinical Follow-up
Prospective, multicenter non comparative and observational study (post-market clinical follow-up). Patients operated with PASS OCT® manufactured by MEDICREA® INTERNATIONAL between July 2016 and July 2017.
- Conditions
- Intervertebral Disc Disease, Spondylolisthesis, Spinal Stenosis, Spinal Neoplasms
- Trial name
- NCT02931279
- Testing
- PASS OCT® Spinal System
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Medicrea International
Glioblastoma
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
The purpose of the study is to evaluate the feasibility and safety of intra-tumor and interstitial therapy with hBMP4 in increasing doses in patients with progressive and/or multiple recurrent Glioblastoma multiforme (GBM).
- Trial name
- NCT02869243
- Testing
- hrBMP4
- Where
- 4 sites in Israel, Italy and 1 more
- Volunteers
- 15 people
- Sponsor
- Stemgen
Refractory Osteosarcoma, Recurrent Osteosarcoma
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma
The purpose of this study, a single-center, open, single-dose clinical study, was to evaluate the safety, tolerability, and pharmacokinetic profile of IM83 CAR-T cells in the treatment of patients with relapsed or refractory…
- Trial name
- NCT06412458
- Testing
- IM83 CAR-T Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Chronic Myeloid Leukemia
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
This trial is a multicenter, open label, randomized phase III clinical study that evaluates the efficacy of oral HS-10382 versus investigator selected TKIs (imatinib, nilotinib, dasatinib, and flumatinib) in newly diagnosed…
- Trial name
- NCT07885293
- Testing
- HS-10382, Imatinib, Dasatinib
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be…
- Conditions
- Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome
- Trial name
- NCT03459534
- Testing
- Radotinib HCl
- Where
- 18 sites in Russia, South Korea and 2 more
- Volunteers
- 173 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Breast Neoplasms
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone…
- Trial name
- NCT02258464
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Background hormonal therapy
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Polycythemia Vera (PV)
A Study to Evaluate P1101 in Japanese PV Patients
This is a Phase 3 single arm study to investigate efficacy and safety of P1101's rapid titration for adult Japanese patients with PV.
- Trial name
- NCT06002490
- Testing
- P1101, Low-dose aspirin, Phlebotomy
- Where
- 6 sites in Japan
- Volunteers
- 21 people
- Sponsor
- PharmaEssentia Japan K.K.
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.